ArticleNeurology2025
Association of Polygenic Susceptibility to Hyperlipidemia With Cholesterol Control and Recurrent Stroke in Ischemic Stroke Survivors.
Article in Neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
BACKGROUND AND
objectivesCommon genetic variation significantly influences the risk of stroke, and previous research has indicated that polygenic susceptibility to hypertension and diabetes negatively affects the clinical trajectory of ischemic stroke survivors. We hypothesize that polygenic susceptibility to hyperlipidemia (PSH) negatively affects cholesterol control in this same population.
methodsWe conducted a genetic association study using data from the Vitamin Intervention Stroke Prevention (VISP) study, a clinical trial that enrolled survivors of ischemic stroke. PSH was modeled using a polygenic risk score built with 38 independent genetic risk variants for low-density lipoprotein cholesterol (LDL-c), which was divided into <20, 20-80, and >80 percentile categories labeled as low, intermediate, and high PSH, respectively. We used multivariable linear, logistic, and Cox regression, as appropriate, to test whether high PSH was associated with risk of uncontrolled hyperlipidemia (HLD) (LDL-c >100 mg/dL), resistant HLD (LDL-c >100 mg/dL despite statin treatment), and clinical outcomes. We replicated our findings in a cohort of ischemic stroke survivors enrolled in the UK Biobank.
resultsA total of 1,567 ischemic stroke survivors (mean age 68 years, 35% female) enrolled in VISP were included in the study. Stroke survivors with higher vs low PSH had 66% higher risk of uncontrolled HLD (OR 1.66, 95% CI 1.17-2.35), 80% higher risk of resistant HLD (1.80, 95% CI 0.99-3.29), twice the risk of recurrent stroke (hazard ratio [HR] 2.12, 95% CI 1.19-3.78), and 87% higher risk of acute coronary events (HR 1.87, 95% CI 1.21-2.87). The association between high PSH and higher risk of uncontrolled and resistant HLD was replicated in 1,634 stroke survivors (mean age 61, 32% female) enrolled in the UK Biobank (OR 2.34, 95% CI 1.67-3.27, and OR 2.33, 95% CI 1.61-3.37, respectively). DISCUSSION: Among acute ischemic stroke survivors, higher PSH is associated with worse lipid control and higher risk of recurrent vascular events. Our findings, combined with existing evidence on the role of adverse genetic profiles in blood pressure and glycemic control in this population, support the comprehensive evaluation of polygenic profiles as a cause of failed risk factor control in stroke survivors and its role in developing precision medicine tools for post-stroke clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.